ID
45382
Beschrijving
Principal Investigator: Matthew Meyerson, MD, PhD, Broad Institute, Cambridge MA, Dana Farber Cancer Institute, Boston MA, USA MeSH: Carcinoma, Non-Small-Cell Lung https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000488 Lung carcinoma is the leading cause of cancer death in the United States and world-wide; lung adenocarcinoma is the most common cause of lung cancer. Pilot studies of lung adenocarcinoma with hybrid-capture based whole exome sequencing will enable us to identify new targets for therapy and improve diagnosis. We will analyze a blend of whole exome and whole genome sequencing data as well as copy number and somatic mutation calls for 200 tumor and matched normal controls. When completed this study will represent the most comprehensive lung adenocarcinoma genome dataset to date.
Link
https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000488
Trefwoorden
Versies (2)
- 09-11-22 09-11-22 - Dr. med. Lucy Kessler
- 13-12-22 13-12-22 - Kristina Keller
Houder van rechten
Matthew Meyerson, MD, PhD, Broad Institute, Cambridge MA, Dana Farber Cancer Institute, Boston MA, USA
Geüploaded op
9 november 2022
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
dbGaP phs000488 Genomic Sequencing of Lung Adenocarcinoma
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants with lung adenocarcinoma and involved in the "Genomic Sequencing of Lung Adenocarcinoma" project.
- Sample ID, subject ID, and sample use variables obtained from participants with lung adenocarcinoma and involved in the "Genomic Sequencing of Lung Adenocarcinoma" project.
- Subject ID, age, ethnicity, pathological diagnosis of tumors, tumor stage, and smoking status of participants with lung adenocarcinoma and involved in the "Genomic Sequencing of Lung Adenocarcinoma" project.
- Sample ID, analyte type, tumor status, hospital diagnosis, and body site where samples were obtained from participants with lung adenocarcinoma and involved in the "Genomic Sequencing of Lung Adenocarcinoma" project.
Similar models
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants with lung adenocarcinoma and involved in the "Genomic Sequencing of Lung Adenocarcinoma" project.
- Sample ID, subject ID, and sample use variables obtained from participants with lung adenocarcinoma and involved in the "Genomic Sequencing of Lung Adenocarcinoma" project.
- Subject ID, age, ethnicity, pathological diagnosis of tumors, tumor stage, and smoking status of participants with lung adenocarcinoma and involved in the "Genomic Sequencing of Lung Adenocarcinoma" project.
- Sample ID, analyte type, tumor status, hospital diagnosis, and body site where samples were obtained from participants with lung adenocarcinoma and involved in the "Genomic Sequencing of Lung Adenocarcinoma" project.